{"id":"NCT00623636","sponsor":"Allergan","briefTitle":"Phase 3 Study of MAP0004 in Adult Migraineurs","officialTitle":"A Randomized, Double Blind, Placebo Controlled, Parallel Group, Phase 3 Study of MAP0004 in Adult Migraineurs for a Single Migraine Followed by Open Label Extension.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07","primaryCompletion":"2010-12","completion":"2011-01","firstPosted":"2008-02-26","resultsPosted":"2013-10-29","lastUpdate":"2014-01-09"},"enrollment":902,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine Disorders"],"interventions":[{"type":"DRUG","name":"MAP0004","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"MAP0004","type":"EXPERIMENTAL"},{"label":"Placebo","type":"OTHER"}],"summary":"This is a randomized, double blind, placebo controlled, parallel group study of MAP0004 in adult migraineurs. Subjects will self administer study drug in the outpatient setting.","primaryOutcome":{"measure":"Number of Subjects With Pain Relief at 2 Hours From Time of First Dose","timeFrame":"2 hours from time of first dose","effectByArm":[{"arm":"Placebo","deltaMin":136,"sd":null},{"arm":"MAP0004","deltaMin":231,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["22106843","21964172","21457235"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":404},"commonTop":["Upper Respiratory Tract Infection","Nausea","Nasopharyngitis","Pharmaceutical Product Compaint","Sinusitis"]}}